Catalent to Acquire Delphi Genetics

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility.

Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million in cash, subject to customary closing adjustments. The transaction is expected to close by the end of the first quarter of 2021, subject to regulatory requirements and customary closing conditions. Cognate is supported by its majority shareholder, EW Healthcare Partners, as well as minority shareholders, Medivate Partners, BlackRock, and a sovereign wealth fund.

WACKER Strengthens Biologics Business by Acquiring US-Based Plasmid DNA Manufacturer Genopis

The Munich-based chemical company WACKER is acquiring 100 percent of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea). WACKER will continue Genopis’ existing customer relationships as a contract manufacturer (CDMO) for plasmid DNA (pDNA). The total purchase price for the acquisition consists of a $39 million cash payment due upon closing as well as possible further performance-based payments under a so-called earn-out model. The transaction is expected to close in the 1st quarter of 2021.

Life Science Outsourcing Partners with PPC Enterprises

Life Science Outsourcing, Inc. (“LSO” or the “Company”), an established certified contract manufacturer and value-added service provider to medical device and life science companies, is pleased to announce that it has received a majority equity investment from New York-based PPC Enterprises LLC (“PPC”), a leading private equity firm focused on service businesses in North America. LSO, which is headquartered in Brea, California, has successfully worked with more than 850 medical device startups as a trusted outsource partner by accelerating product speed to market and enabling customers to continually develop increasingly complex and innovative commercial medical devices.

The Vistria Group and Excellere Partners Invest in SCA Pharmaceuticals

SCA Pharmaceuticals, LLC (“SCA Pharma”), has entered into a definitive membership interest purchase agreement with The Vistria Group (“Vistria”) and Excellere Partners (“Excellere”). SCA Pharma, an FDA-registered outsourcing facility, serves over 1,200 hospitals and health systems in the United States. The company provides compounded drugs that are otherwise not commercially available, filling a critical void in the pharmaceutical drug landscape.

NovaQuest Private Equity Acquires CoreRx, Inc.

NovaQuest Private Equity (“NovaQuest”) announced Tuesday its acquisition of CoreRx, Inc. (“CoreRx” or the “Company”), a global contract development and manufacturing organization (“CDMO”). Based in Clearwater, FL, CoreRx provides clinical and commercial CDMO services to a wide range of small to mid-sized pharmaceutical and biotech clients. Founded in 2006, the Company offers preformulation, formulation, analytical and stability, clinical manufacturing, commercial manufacturing, and packaging services.

ARCH Global Precision Acquires LISI Medical Jeropa, Inc.

ARCH Global Precision (“ARCH”) has acquired LISI Medical Jeropa, Inc. (“LISI Jeropa”) located in Escondido, California. A subsidiary of LISI Medical, the Jeropa plant is a leading contract manufacturer of high-precision medical implants, instruments, and other devices serving a variety of segments in the orthopaedic, dental, and cardiovascular markets. The newly acquired plant and operations will join ARCH Medical Solutions (“AMS”), bolstering ARCH as a diversified supplier noted for growth and scale within the medical device market.

Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep

Thermo Fisher Scientific Inc., (NYSE: TMO), the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry, today announced that Thermo Fisher has completed the acquisition of Henogen S.A., Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash. Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers.

Serán Bioscience Announces Investment by Vivo Capital

Serán Bioscience today announced that healthcare investment firm Vivo Capital has made a majority investment in Serán alongside Serán’s founders who will continue to lead the Company. Founded in 2016, Serán is a leading contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. Serán’s deep experience and expertise in materials science, formulation development, engineering, and pharmaceutical manufacturing enables optimum solutions for their customers most difficult drug development challenges.

MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics

MilliporeSigma today announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens MilliporeSigma’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases.